## Johan Vallon-Christersson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3446423/publications.pdf

Version: 2024-02-01

61 papers

6,431 citations

126708 33 h-index 62 g-index

68 all docs 68
docs citations

68 times ranked 11097 citing authors

#	Article	IF	CITATIONS
1	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature, 2020, 577, 561-565.	13.7	1,209
2	Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype. Cancer Cell, 2006, 10, 413-423.	7.7	624
3	BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biology, 2002, 3, software0003.1.	13.9	359
4	Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nature Genetics, 2008, 40, 102-107.	9.4	316
5	Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nature Communications, 2017, 8, 1738.	<b>5.</b> 8	310
6	Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Research, 2010, 12, R36.	2.2	251
7	Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nature Medicine, 2019, 25, 1526-1533.	15.2	218
8	Identification of New MicroRNAs in Paired Normal and Tumor Breast Tissue Suggests a Dual Role for the <i>ERBB2/Her2</i> Gene. Cancer Research, 2011, 71, 78-86.	0.4	191
9	High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes and Cancer, 2007, 46, 543-558.	1.5	176
10	CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer, 2011, 11, 418.	1.1	173
11	Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Research, 2010, 12, R42.	2.2	167
12	Distinct Genomic Profiles in Hereditary Breast Tumors Identified by Array-Based Comparative Genomic Hybridization. Cancer Research, 2005, 65, 7612-7621.	0.4	147
13	The non-coding RNA of the multidrug resistance-linked vault particle encodes multiple regulatory small RNAs. Nature Cell Biology, 2009, 11, 1268-1271.	4.6	147
14	Identification of Subtypes in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome. Journal of Clinical Oncology, 2010, 28, 1813-1820.	0.8	145
15	An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. Nature Communications, 2019, 10, 5499.	5.8	132
16	The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Medicine, 2015, 7, 20.	3.6	129
17	High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Research, 2010, 12, R25.	2.2	123
18	Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth, survival, and aggressive behavior. Experimental Cell Research, 2004, 295, 469-487.	1.2	114

#	Article	IF	CITATIONS
19	Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative. JCO Precision Oncology, 2018, 2, 1-18.	1.5	101
20	Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma. Clinical Cancer Research, 2012, 18, 4026-4036.	3.2	96
21	Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma. Cancer Research, 2016, 76, 4765-4774.	0.4	86
22	Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Molecular Cancer, 2010, 9, 107.	7.9	77
23	An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells. Breast Cancer Research, 2016, 18, 27.	2.2	67
24	Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells. Oncogene, 2004, 23, 4050-4059.	2.6	66
25	Normalization of array-CGH data: influence of copy number imbalances. BMC Genomics, 2007, 8, 382.	1.2	57
26	Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nature Communications, 2020, 11, 3747.	5.8	53
27	Gene expression profiles relate to SS18/SSX fusion type in synovial sarcoma. International Journal of Cancer, 2006, 118, 1165-1172.	2.3	52
28	BASE - 2nd generation software for microarray data management and analysis. BMC Bioinformatics, 2009, 10, 330.	1.2	45
29	Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours. Breast Cancer Research and Treatment, 2012, 133, 583-594.	1.1	44
30	Characterization of a Novel Breast Carcinoma Xenograft and Cell Line Derived from a BRCA1 Germ-Line Mutation Carrier. Laboratory Investigation, 2003, 83, 387-396.	1.7	43
31	The Retinoblastoma Gene Undergoes Rearrangements in <i>BRCA1</i> Cancer. Cancer Research, 2012, 72, 4028-4036.	0.4	41
32	Serum selenium, selenoprotein P and glutathione peroxidase 3 as predictors of mortality and recurrence following breast cancer diagnosis: A multicentre cohort study. Redox Biology, 2021, 47, 102145.	3.9	40
33	High expression of <scp><i>ZNF703</i></scp> independent of amplification indicates worse prognosis in patients with luminal B breast cancer. Cancer Medicine, 2013, 2, 437-446.	1.3	39
34	Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. Scientific Reports, 2019, 9, 12184.	1.6	39
35	Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort. Clinical Cancer Research, 2019, 25, 6368-6381.	3.2	37
36	The mutational landscape of the <scp>SCAN</scp> â€B realâ€world primary breast cancer transcriptome. EMBO Molecular Medicine, 2020, 12, e12118.	3.3	36

#	Article	IF	CITATIONS
37	Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer. Molecular Cell, 2021, 81, 1453-1468.e12.	4.5	31
38	Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report. Journal of Medical Genetics, 2019, 56, 453-460.	1.5	30
39	Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns. Melanoma Research, 2010, 20, 381-391.	0.6	30
40	The HER2-Encoded miR-4728-3p Regulates ESR1 through a Non-Canonical Internal Seed Interaction. PLoS ONE, 2014, 9, e97200.	1.1	27
41	Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer. Npj Breast Cancer, 2020, 6, 28.	2.3	25
42	Frequent miRNA-convergent fusion gene events in breast cancer. Nature Communications, 2017, 8, 788.	5.8	24
43	Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer. Breast Cancer Research and Treatment, 2019, 178, 459-467.	1.1	23
44	Molecular analyses of triple-negative breast cancer in the young and elderly. Breast Cancer Research, 2021, 23, 20.	2.2	23
45	Tumor genetic heterogeneity analysis of chronic sunâ€damaged melanoma. Pigment Cell and Melanoma Research, 2020, 33, 480-489.	1.5	22
46	Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns. Melanoma Research, 2010, 20, 381-91.	0.6	22
47	A Naturally Occurring Allele of BRCA1 Coding for a Temperature-Sensitive Mutant Protein. Cancer Biology and Therapy, 2002, 1, 497-501.	1.5	20
48	Preexisting Somatic Mutations of Estrogen Receptor Alpha ( <i>ESR1</i> ) in Early-Stage Primary Breast Cancer. JNCI Cancer Spectrum, 2021, 5, pkab028.	1.4	20
49	Nonsense-mediated mRNA decay in barley mutants allows the cloning of mutated genes by a microarray approach. Plant Physiology and Biochemistry, 2004, 42, 681-685.	2.8	18
50	Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation. Npj Genomic Medicine, 2019, 4, 7.	1.7	18
51	Performance of gene expression–based single sample predictors for assessment of clinicopathological subgroups and molecular subtypes in cancers: a case comparison study in non-small cell lung cancer. Briefings in Bioinformatics, 2020, 21, 729-740.	3.2	17
52	[7] An Introduction to BioArray Software Environment. Methods in Enzymology, 2006, 411, 99-119.	0.4	12
53	Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer. Cancers, 2021, 13, 6118.	1.7	10
54	Non-coding antisense transcription detected by conventional and single-stranded cDNA microarray. BMC Genomics, 2007, 8, 295.	1.2	9

#	Article	IF	CITATIONS
55	Autoimmunity to selenoprotein P predicts breast cancer recurrence. Redox Biology, 2022, 53, 102346.	3.9	9
56	Analysis of fusion transcripts indicates widespread deregulation of snoRNAs and their host genes in breast cancer. International Journal of Cancer, 2020, 146, 3343-3353.	2.3	8
57	Methylation Patterns and Chromatin Accessibility in Neuroendocrine Lung Cancer. Cancers, 2020, 12, 2003.	1.7	5
58	Regulatory networks and 5′ partner usage of <scp>miRNA</scp> host gene fusions in breast cancer. International Journal of Cancer, 2022, 151, 95-106.	2.3	5
59	Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns. International Journal of Cancer, 2021, 148, 884-894.	2.3	3
60	Interval breast cancer is associated with interferon immune response. European Journal of Cancer, 2022, 162, 194-205.	1.3	3
61	Abstract P2-08-11: How reliable are biomarkers assessed on a core needle biopsy? A study of paired core needle biopsies and surgical specimens in early breast cancer. Cancer Research, 2022, 82, P2-08-11-P2-08-11.	0.4	0